Cargando…
Development of a Fluorescent Quenching Based High Throughput Assay to Screen for Calcineurin Inhibitors
Currently there is no effective treatment available for major neurodegenerative disorders associated to protein misfolding, including Alzheimer’s and Parkinson's disease. One of most promising therapeutic approaches under development focuses on inhibiting the misfolding and aggregation pathway....
Autores principales: | Mukherjee, Abhisek, Syeb, Kathleen, Concannon, John, Callegari, Keri, Soto, Claudio, Glicksman, Marcie A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503349/ https://www.ncbi.nlm.nih.gov/pubmed/26176772 http://dx.doi.org/10.1371/journal.pone.0131297 |
Ejemplares similares
-
Development of a novel pharmacophore model to screen specific inhibitors for the serine-threonine protein phosphatase calcineurin
por: Mukherjee, Abhisek, et al.
Publicado: (2022) -
High-Throughput Fluorescent Assay for Inhibitor Screening of Proteases from RNA Viruses
por: Cihlova, Bara, et al.
Publicado: (2021) -
Calcineurin Inhibition at the Clinical Phase of Prion Disease Reduces Neurodegeneration, Improves Behavioral Alterations and Increases Animal Survival
por: Mukherjee, Abhisek, et al.
Publicado: (2010) -
Fluorescence Resonance Energy Transfer Assay for High-Throughput Screening of ADAMTS1 Inhibitors
por: Peng, Jianhao, et al.
Publicado: (2011) -
Calcineurin Inhibitors in Membranous Nephropathy
por: Ponticelli, Claudio, et al.
Publicado: (2021)